Literature DB >> 22416207

Comparative activity of several antimicrobial agents against nosocomial Gram-negative rods isolated across Canada.

S R Scriver1, D E Low.   

Abstract

In 1992, a surveillance study was performed in Canada to determine the susceptibility of nosocomial Gram-negative rods to several wide spectrum antimicrobials. Consecutive isolates from 10 institutions, as well as additional strains of selected species of Enterobacteriaceae that are known to possess the Bush group 1 beta-lactamase, were tested for susceptibility to 12 antimicrobials. Third-generation cephalosporin resistance was found to be as high as 29% in Enterobacter cloacae that possesses the Bush group 1 beta-lactamase and less than 4% in those isolates not possessing this enzyme. Cefepime equalled or exceeded the activity of the third-generation cephalosporins against the species of Enterobacteriaceae that demonstrated resistance to the third-generation cephalosporins.

Entities:  

Keywords:  Antimicrobial resistance; Gram-negative rods

Year:  1995        PMID: 22416207      PMCID: PMC3298055          DOI: 10.1155/1995/297910

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN: 1180-2332


  23 in total

Review 1.  Characterization of beta-lactamases.

Authors:  K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

2.  Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility.

Authors:  L B Rice; S H Willey; G A Papanicolaou; A A Medeiros; G M Eliopoulos; R C Moellering; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 3.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 4.  Extended-spectrum beta-lactamases.

Authors:  A Philippon; R Labia; G Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 5.  Chromosomal cephalosporinases responsible for multiple resistance to newer beta-lactam antibiotics.

Authors:  C C Sanders
Journal:  Annu Rev Microbiol       Date:  1987       Impact factor: 15.500

6.  Factors that influence the evolution of beta-lactam resistance in beta-lactamase-inducible strains of Enterobacter cloacae and Pseudomonas aeruginosa.

Authors:  S C Aronoff; D M Shlaes
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

7.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.

Authors:  H Knothe; P Shah; V Krcmery; M Antal; S Mitsuhashi
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

8.  In-vitro antibacterial activity of cefepime: a multicentre study.

Authors:  J Duval; C J Soussy; J F Acar; E Bergogne-Bérézin; R Cluzel; A Thabaut; P Courvalin; J J Grès; C Rollin
Journal:  J Antimicrob Chemother       Date:  1993-11       Impact factor: 5.790

Review 9.  The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens.

Authors:  R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1992-02       Impact factor: 2.803

10.  Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae.

Authors:  J P Quinn; D Miyashiro; D Sahm; R Flamm; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

View more
  4 in total

1.  In vitro activity of cefepime against multidrug-resistant Gram-negative bacilli, viridans group streptococci and Streptococcus pneumoniae from a cross-Canada surveillance study.

Authors:  D E Low; J de Azavedo; R Davidson
Journal:  Can J Infect Dis       Date:  1999-03

2.  Low prevalence of gastrointestinal colonization with antimicrobial-resistant bacteria in high risk units in a Canadian tertiary care centre.

Authors:  J M Embil; A Kabani; G Zhanel; L E Nicolle
Journal:  Can J Infect Dis       Date:  1996-09

3.  Decision analysis modelling of costs and outcomes following cefepime monotherapy in Canada.

Authors:  M T Halpern; R E Brown; M Drolet; S V Sorensen; L A Mandell
Journal:  Can J Infect Dis       Date:  1997-01

4.  Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates.

Authors:  K R Forward; D E Low; M Laverdiere; R Rennie; A E Simor; P A Franks
Journal:  Can J Infect Dis       Date:  1997-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.